Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 20, 2017
Pharmacy Choice - Pharmaceutical News - Flexion Therapeutics Announces Upcoming Data Presentation at the American Diabetes Association`s 77th Scientific Sessions [Sudan Tribune] - October 20, 2017

Pharmacy News Article

 5/19/17 - Flexion Therapeutics Announces Upcoming Data Presentation at the American Diabetes Association`s 77th Scientific Sessions [Sudan Tribune]

(GlobeNewswire) - Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the upcoming presentation of the full results from a Phase 2 clinical trial of its lead investigational product candidate, Zilretta (FX006), in patients with Type 2 diabetes and osteoarthritis (OA) of the knee. The data will be presented during the American Diabetes Association`s 77th Scientific Sessions, taking place in San Diego from June 9-13.

In November 2016, Flexion reported positive top-line results from the trial which was designed to examine blood glucose concentrations following an injection of Zilretta compared with immediate-release triamcinolone acetonide in crystalline suspension.

The data will be discussed in a poster titled, In Type 2 Diabetes Mellitus Patients with Knee Osteoarthritis Intra-articular Injection of FX006 (Extended Release Triamcinolone) is Associated with Reduced Blood Glucose Elevation vs. Standard Triamcinolone; a Randomized, Blinded, Parallel-group Study (#1091-P) on Sunday, June 11, 2017, from 12:00 p.m. - 1:00 p.m. Additional information can be found on the American Diabetes Associations website.

About Osteoarthritis of the KneeWhile OA is being diagnosed at increasingly younger ages, prevalence rises after age 45. In 2015, more than 14 million Americans were diagnosed with OA of the knee. OA represents an enormous burden on the U.S. healthcare system, affecting approximately 31 million individuals and accounting for more than $185 billion in annual expenditures. About 13 percent of women and 10 percent of men aged 60 years and older have symptomatic OA of the knee, with rates likely to increase due to the aging of the population and the rate of obesity or overweight individuals in the general population.

Each year, more than five million OA patients in the United States receive either an immediate-release corticosteroid or hyaluronic acid intra-articular injection for knee pain.

About ZilrettaZilretta is being investigated as the first intra-articular, extended-release treatment for patients with OA related knee pain. Zilretta employs proprietary microsphere technology combining TA a commonly administered, short-acting corticosteroid with a poly lactic-co-glycolic acid (PLGA) matrix. To date, more than 800 patients have been treated with Zilretta in clinical trials.

About Flexion TherapeuticsFlexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company`s lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.

Corporate Contact:

Scott Young

Sr. Director, Corporate Communications & Investor Relations

Flexion Therapeutics, Inc.

T: 781-305-7194

syoung@flexiontherapeutics.com



(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Oct 23: Vitamin D Primer for Pharmacy Professionals
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415